Background: Colorectal cancer is one of the most common malignant tumors in China. The aims of this research were to increase the sensitivity of anti-p53 antibody detection in the sera of patients with colorectal cancer and to assist in their diagnosis. Methods: Sixty-seven non-selected Chinese with colorectal cancer were involved in this study. Anti-p53 antibodies in serum were detected by ELISA using recombinant human wild-type p53 protein and hybrid phage as the coating antigen. Correlations between the anti-p53 antibodies and clinicopathological parameters were also analyzed. Results: The detection efficiency of anti-p53 antibodies in the patients with colorectal cancer was increased (46.3%, 31/67) through the combination of the two ELISA methods compared with each method alone. The titer of serum anti-p53 antibodies was not associated with clinicopathological parameters, but there was a significant correlation between their presence, the CEA level, and the stage of the patient’s colorectal cancer. Conclusions: These results demonstrate that combination of the two ELISA methods increased the detection rate of anti-p53 antibodies in patients with colorectal cancer. This research may provide a useful method to complement conventional clinical diagnosis.
(2011). Detection of Serum Anti-P53 Antibodies from Patients with Colorectal Cancer in China Using a Combination of P53- and phage-ELISA: Correlation to Clinical Parameters. Asian Pacific Journal of Cancer Prevention, 12(11), 2921-2924.
MLA
. "Detection of Serum Anti-P53 Antibodies from Patients with Colorectal Cancer in China Using a Combination of P53- and phage-ELISA: Correlation to Clinical Parameters". Asian Pacific Journal of Cancer Prevention, 12, 11, 2011, 2921-2924.
HARVARD
(2011). 'Detection of Serum Anti-P53 Antibodies from Patients with Colorectal Cancer in China Using a Combination of P53- and phage-ELISA: Correlation to Clinical Parameters', Asian Pacific Journal of Cancer Prevention, 12(11), pp. 2921-2924.
VANCOUVER
Detection of Serum Anti-P53 Antibodies from Patients with Colorectal Cancer in China Using a Combination of P53- and phage-ELISA: Correlation to Clinical Parameters. Asian Pacific Journal of Cancer Prevention, 2011; 12(11): 2921-2924.